ConductScience.org, home

Paper41764403

Ultrasound-Responsive Engineered Bacteria for Targeted Cancer Therapy: Strategies, Mechanisms, and Applications.

Wang X and 5 others. Adv Sci (Weinh), 2026. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. Ultrasound-Responsive Engineered Bacteria for Targeted Cancer Therapy: Strategies, Mechanisms, and Applications. Papers, record 41764403. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41764403

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Ultrasound-Responsive Engineered Bacteria for Targeted Cancer Therapy: Strategies, Mechanisms, and Applications.
PubMed
Journal
Adv Sci (Weinh)
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
1
iCite
Revised in PubMed
2026-08-13
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wang XXueyao
2Xu WWenjing
3Lu YYafang
4Yu HHuaibinhttps://orcid.org/0000-0002-1570-5092
5Zha ZZhengbaohttps://orcid.org/0000-0003-3646-4969
6Zhang XXijun

Source PubMed

Download CSV of authors

Topics5

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
NeoplasmsMajor topic
BacteriaMajor topic
Drug Delivery SystemsMajor topic
Humans
Animals

Grants8

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
CUGD0200400424Harbin Institute of Technology Zhengzhou Research Institute Research Launch FundPubMed
CUGD0200600223Harbin Institute of Technology Zhengzhou Research Institute Research Launch FundPubMed
CUGD0200800125Young Scientists StudioPubMed
242102311235Henan Provincial Science and Technology Research ProjectPubMed
254200510053Henan Province Science and Technology Innovation Talent ProgramPubMed
2024M754162Postdoctoral Research Foundation of ChinaPubMed
52522215National Natural Science Foundation of ChinaPubMed
82171963National Natural Science Foundation of ChinaPubMed

Source PubMed

Download CSV of grants

References101

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
140104641Ultrasound-responsive engineered bacteria mediated specific controlled expression of catalase and efficient radiotherapy.Mater Today Bio2025https://conductscience.org/library/papers/40104641PubMed
235708251Tunable Temperature-Sensitive Transcriptional Activation Based on Lambda Repressor.ACS Synth Biol2022https://conductscience.org/library/papers/35708251PubMed
338487163Ultrasound combined with microbubble mediated immunotherapy for tumor microenvironment.Front Pharmacol2024https://conductscience.org/library/papers/38487163PubMed
438975322Ultrasound -Induced Thermal Effect Enhances the Efficacy of Chemotherapy and Immunotherapy in Tumor Treatment.Int J Nanomedicine2024https://conductscience.org/library/papers/38975322PubMed
539208935The advance of ultrasound-enabled diagnostics and therapeutics.J Control Release2024https://conductscience.org/library/papers/39208935PubMed
639834364A comprehensive review of probiotics and human health-current prospective and applications.Front Microbiol2024https://conductscience.org/library/papers/39834364PubMed
737875910Engineered live bacteria as disease detection and diagnosis tools.J Biol Eng2023https://conductscience.org/library/papers/37875910PubMed
840680134Acoustic technologies for the orchestration of cellular functions for therapeutic applications.Sci Adv2025https://conductscience.org/library/papers/40680134PubMed
934374945High-Intensity Focused Ultrasound: A Review of Mechanisms and Clinical Applications.Ann Biomed Eng2021https://conductscience.org/library/papers/34374945PubMed
1033114050Doxorubicin Improves Cancer Cell Targeting by Filamentous Phage Gene Delivery Vectors.Int J Mol Sci2020https://conductscience.org/library/papers/33114050PubMed
1135985374The promising interplay between sonodynamic therapy and nanomedicine.Adv Drug Deliv Rev2022https://conductscience.org/library/papers/35985374PubMed
1232843638The updated landscape of tumor microenvironment and drug repurposing.Signal Transduct Target Ther2020https://conductscience.org/library/papers/32843638PubMed
1331941712Near-infrared optogenetic engineering of photothermal nanoCRISPR for programmable genome editing.Proc Natl Acad Sci U S A2020https://conductscience.org/library/papers/31941712PubMed
1438610042Bacteria-driven nanosonosensitizer delivery system for enhanced breast cancer treatment through sonodynamic therapy-induced immunogenic cell death.J Nanobiotechnology2024https://conductscience.org/library/papers/38610042PubMed
1530837696Engineering advanced cancer therapies with synthetic biology.Nat Rev Cancer2019https://conductscience.org/library/papers/30837696PubMed
1639395706Multi-functional nanosonosensitizer-engineered bacteria to overcome tumor hypoxia for enhanced sonodynamic therapy.Acta Biomater2024https://conductscience.org/library/papers/39395706PubMed
1734166726Targeting hypoxia for sensitization of tumors to apoptosis enhancement through supramolecular biohybrid bacteria.Int J Pharm2021https://conductscience.org/library/papers/34166726PubMed
1838481806NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer.Int J Biol Sci2024https://conductscience.org/library/papers/38481806PubMed
1936213533Macrophage-mediated tumor-targeted delivery of engineered Salmonella typhi murium VNP20009 in anti-PD1 therapy against melanoma.Acta Pharm Sin B2022https://conductscience.org/library/papers/36213533PubMed
2038858780Bacterial outer membrane vesicle-cancer cell hybrid membrane-coated nanoparticles for sonodynamic therapy in the treatment of breast cancer bone metastasis.J Nanobiotechnology2024https://conductscience.org/library/papers/38858780PubMed

See all 101 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.

PMIDTitleJournalYearIn PapersSource
42964597Engineered live biotherapeutic products: design decisions, failure modes, and clinical translation.Front Microbiol2026https://conductscience.org/library/papers/42964597PubMed
42530837Bacterial-based cancer therapy: mechanisms and therapeutic advances.Mol Biomed2026https://conductscience.org/library/papers/42530837PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41764403

GET https://conductscience.org/api/papers/v1/41764403/references?page=2